drugset / Trial / NCT00207090

Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer

NCT00207090

Phase 1 Completed 19 enrolled R-Pharm
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test how rifampin affects the removal of BMS-247550 (ixabepilone) from the body.

Timeline

Start
2005-09
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Ixabepilone Small molecule 40 mg/m2 Intravenous
Subject Rifampin Small molecule 600 mg Oral

Indications